NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration has today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention to be held at the San Diego Convention Center, Monday, June 13 through Thursday, June 16 2022. His presentation will primarily focus on recent clinical updates on the nasal delivery of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of patients with secondary progressive multiple sclerosis. He will also provide an update on the initiation of the Phase 1b trial with the “first” foralumab oral capsules for the treatment of patients with mild to moderate active Crohn’s disease. Company management will also participate in one-on-one meetings throughout the conference.
Presenter: Kunwar Shailubhai, Ph.D., Chief Executive Officer and Chief Scientific Officer, Tiziana Life Sciences
Title: Enabling breakthrough immunotherapies via novel drug delivery routes
Day: Tuesday, June 14
Time: 2:00 p.m. – 2:15 p.m. PDT
Location: Theater 1
To register for the conference and schedule a one-on-one meeting with Tiziana Life Sciences leadership, please visit https://www.bio.org/events/bio-international-convention/registration.
Dr. Shailubhai will also attend BioNJ’s 29th Annual Dinner Gathering and Celebration of Innovation, bringing together and honoring members of New Jersey’s life sciences ecosystem, on Thursday, June 9, 2022 at 4:45 p.m. EDT . This meeting, which was held at the Hilton in East Brunswick, New Jersey, was originally scheduled for February and was postponed due to the rise of the Omicron variant.
About BIO and the BIO International Convention
The Biotechnology Innovation Organization (BIO) is the world’s largest biotechnology organization, providing advocacy, business development and communications services to more than 1,200 members worldwide. Our mission is to be the biotechnology champion and advocate for our member organizations, large and small. BIO members are involved in the research and development of innovative biotechnological technologies in the fields of health, agriculture, industry and the environment. Member companies range from entrepreneurial companies developing a first product to Fortune 100 multinationals. We also represent national and regional biotechnology associations, industry service providers and academic centers. Currently, more than 3,000 international and domestic companies are registered to participate in BIO 2022 in the biotech industry.
Founded in 1994, BioNJ, BIO’s New Jersey partner, has worked hard in its mission to improve the life sciences climate in the state. As a representative of an industry that has the potential to change the course of human health, make our environment cleaner and the foods we eat safer and healthier, BioNJ is determined in its commitment to growth and prosperity of this industry within the state. from New Jersey.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The novel intranasal, oral and inhalation approaches to Tiziana under development have the potential to improve efficacy as well as safety and tolerability compared to intravenous (IV) administration. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies nowadays. Tiziana’s technology for alternative immunotherapy pathways has been patented with several pending applications and is expected to enable broad pipeline applications.
For more information, please contact:
Tiziana Life Sciences:
Hana Malik, Head of Business Development and Investor Relations
+44 (0) 207 495 2379
Tel: (646) 970-4681
Copyright 2022 GlobeNewswire, Inc.